Development of a time-resolved fluorescence resonance energy transfer assay for cyclin-dependent kinase 4 and identification of its ATP-noncompetitive inhibitors

Analytical Biochemistry

Volumn 421, Issue 2, 2012, Pages 368-377

  Lo, Mei Chu ^a   Ngo, Rachel ^a   Dai, Kang ^a   Li, Cong ^a   Liang, Lingming ^a   Lee, Josie ^a   Emkey, Renee ^a   Eksterowicz, John ^a   Ventura, Manuel ^a   Young, Stephen W ^a   Xiao, Shou Hua ^a  

^a AMGEN INC   (United States)

Author keywords

ATP noncompetitive; CDK4; High throughput screening; Inhibitor; Kinase; TR FRET

Indexed keywords

DIAGNOSIS; ENERGY TRANSFER; ENZYMES;

CDK4; HIGH THROUGHPUT SCREENING; INHIBITOR; KINASE; TR-FRET;

FORSTER RESONANCE ENERGY TRANSFER;

CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 4 INHIBITOR; ENZYME INHIBITOR; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ARTICLE; CONTROLLED STUDY; ENZYME ANALYSIS; ENZYME KINETICS; FLUORESCENCE RESONANCE ENERGY TRANSFER; HIGH THROUGHPUT SCREENING; INHIBITION KINETICS; NONCOMPETITIVE INHIBITION; PRIORITY JOURNAL;

EID: 84859724562     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2011.10.014     Document Type: Article

References (40)

1. P. Cohen, The development and therapeutic potential of protein kinase inhibitors, Curr. Opin. Chem. Biol. 3 (1999) 459-465. (Pubitemid 29376108)
2. M.A. Arslan, O. Kutuk, H. Basaga, Protein kinases as drug targets in cancer, Curr. Cancer Drug Targets 6 (2006) 623-634. (Pubitemid 44691004)
3. P. Cohen, Targeting protein kinases for the development of anti-inflammatory drugs, Curr. Opin. Cell Biol. 21 (2009) 317-324.
4. L.K. Chico, L.J. Van Eldik, D.M. Watterson, Targeting protein kinases in central nervous system disorders, Nat. Rev. Drug Discov. 8 (2009) 892-909.
5. H. Wesche, S.H. Xiao, S.W. Young, High throughput screening for protein kinase inhibitors, Comb. Chem. High Throughput Screen. 8 (2005) 181-195. (Pubitemid 40392512)
6. F.M. Gribble, G. Loussouarn, S.J. Tucker, C. Zhao, C.G. Nichols, F.M. Ashcroft, A novel method for measurement of submembrane ATP concentration, J. Biol. Chem. 275 (2000) 30046-30049.
7. Z.A. Knight, K.M. Shokat, Features of selective kinase inhibitors, Chem. Biol. 12 (2005) 621-637. (Pubitemid 43142039)
8. W. Davidson, L. Frego, G.W. Peet, R.R. Kroe, M.E. Labadia, S.M. Lukas, R.J. Snow, S. Jakes, C.A. Grygon, C. Pargellis, B.G. Werneburg, Discovery and characterization of a substrate selective p38a inhibitor, Biochemistry 43 (2004) 11658-11671. (Pubitemid 39277611)
9. G. Cozza, A. Bortolato, E. Menta, E. Cavalletti, S. Spinelli, S. Moro, ATP noncompetitive Ser/Thr kinase inhibitors as potential anticancer agents, Anticancer Agents Med. Chem. 9 (2009) 778-786.
10. M.A. Bogoyevitch, D.P. Fairlie, A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding, Drug Discov. Today 12 (2007) 622-633. (Pubitemid 47238645)
11. A. Kiselyov, K.V. Balakin, S.E. Tkachenko, N.P. Savchuk, Recent progress in development of non-ATP competitive small-molecule inhibitors of protein kinases, Mini Rev. Med. Chem. 6 (2006) 711-717. (Pubitemid 43881122)
12. J.S. Sebolt-Leopold, D.T. Dudley, R. Herrera, K. Van Becelaere, A. Wiland, R.C. Gowan, H. Tecle, S.D. Barrett, A. Bridges, S. Przybranowski, W.R. Leopold, A.R. Saltiel, Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo, Nat. Med. 5 (1999) 810-816. (Pubitemid 29318616)
13. J.F. Ohren, H. Chen, A. Pavlovsky, C. Whitehead, E. Zhang, P. Kuffa, C. Yan, P. McConnell, C. Spessard, C. Banotai, W.T. Mueller, A. Delaney, C. Omer, J. Sebolt-Leopold, D.T. Dudley, I.K. Leung, C. Flamme, J. Warmus, M. Kaufman, S. Barrett, H. Tecle, C.A. Hasemann, Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition, Nat. Struct. Mol. Biol. 11 (2004) 1192-1197.
14. M. Malumbres, M. Barbacid, Cell cycle, CDKs, and cancer: a changing paradigm, Nat. Rev. Cancer 9 (2009) 153-166.
15. G.I. Shapiro, Cyclin-dependent kinase pathways as targets for cancer treatment, J. Clin. Oncol. 24 (2006) 1770-1783. (Pubitemid 46628473)
16. M. Orzáez, A. Gortat, L. Mondragón, O. Bachs, E. Pérez-Payá, ATPnoncompetitive inhibitors of CDK-cyclin complexes, ChemMedChem 4 (2009) 19-24.
17. A.J. Kolb, P.V. Kaplita, D.J. Hayes, Y.-W. Park, C. Pernell, J.S. Major, G. Mathis, Tyrosine kinase assays adapted to homogeneous time-resolved fluorescence, Drug Discov. Today 3 (1998) 333-342. (Pubitemid 28331402)
18. I. Hemmilä, S. Dakubu, V.M. Mukkala, H. Siitari, T. Lövgren, Europium as a label in time-resolved immunofluorometric assays, Anal. Biochem. 137 (1984) 335-343.
19. H. Bazin, E. Trinquet, G. Mathis, Time resolved amplification of cryptate emission: a versatile technology to trace biomolecular interactions, J. Biotechnol. 82 (2002) 233-250. (Pubitemid 34179603)
20. T. Förster, Intermolecular energy migration and fluorescence, Ann. Phys. 2 (1948) 55-75.
21. J.R. Lakowicz, Principles of Fluorescence Spectroscopy, third ed., Springer, New York, 2006.
22. D.W. Fry, P.J. Harvey, P.R. Keller, W.L. Elliott, M. Meade, E. Trachet, M. Albassam, X. Zheng, W.R. Leopold, N.K. Pryer, P.L. Toogood, Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts, Mol. Cancer Ther. 3 (2004) 1427-1437. (Pubitemid 39562588)
23. J.H. Zhang, T.D. Chung, K.R. Oldenburg, A simple statistical parameter for use in evaluation and validation of high throughput screening assays, J. Biomol. Screen. 4 (1999) 67-73. (Pubitemid 29278954)
24. 50) of an enzymatic reaction, Biochem. Pharmacol. 22 (1973) 3099-3108.
25. R.A. Copeland, Enzymes: A Practical Introduction to Structure, Mechanism, and Data Analysis, second ed., John Wiley, New York, 2000.
26. Y. Jia, C.M. Quinn, A.I. Gagnon, R. Talanian, Homogeneous time-resolved fluorescence and its applications for kinase assays in drug discovery, Anal. Biochem. 356 (2006) 273-281. (Pubitemid 44291648)
27. M. Kitagawa, H. Higashi, H.K. Jung, I. Suzuki-Takahashi, M. Ikeda, K. Tamai, J. Kato, K. Segawa, E. Yoshida, S. Nishimura, Y. Taya, The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2, EMBO J. 15 (1996) 7060-7069. (Pubitemid 27023276)
28. B. Sarcevic, R. Lilischkis, R.L. Sutherland, Differential phosphorylation of T-47D human breast cancer cell substrates by D1-, D3-, E-, and A-type cyclin-CDK complexes, J. Biol. Chem. 272 (1997) 33327-33337. (Pubitemid 28023683)
29. C. Harbert, J. Marshall, S. Soh, K. Steger, Development of a HTRF kinase assay for determination of Syk activity, Curr. Chem. Genomics 1 (2008) 20-26.
30. D.W. Fry, D.C. Bedford, P.H. Harvey, A. Fritsch, P.R. Keller, Z. Wu, E. Dobrusin, W.R. Leopold, A. Fattaey, M.D. Garrett, Cell cycle and biochemical effects of PD 0183812: a potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6, J. Biol. Chem. 276 (2001) 16617-16623.
31. I. Akritopoulou-Zanze, P.J. Hajduk, Kinase-targeted libraries: the design and synthesis of novel, potent, and selective kinase inhibitors, Drug Discov. Today 14 (2009) 291-297.
32. D. Sun, C. Chuaqui, Z. Deng, S. Bowes, D. Chin, J. Singh, P. Cullen, G. Hankins, W.C. Lee, J. Donnelly, J. Friedman, S. Josiah, A kinase-focused compound collection: compilation and screening strategy, Chem. Biol. Drug Des. 67 (2006) 385-394. (Pubitemid 44086975)
33. M. Payton, G. Chung, P. Yakowec, A. Wong, D. Powers, L. Xiong, N. Zhang, J. Leal, T.L. Bush, V. Santora, B. Askew, A. Tasker, R. Radinsky, R. Kendall, S. Coats, Discovery and evaluation of dual CDK1 and CDK2 inhibitors, Cancer Res. 66 (2006) 4299-4308.
34. J.R. Sportsman, E.A. Gaudet, A. Boge, Immobilized metal ion affinity-based fluorescence polarization (IMAP): advances in kinase screening, Assay Drug Dev. Technol. 2 (2004) 205-214. (Pubitemid 38647430)
35. R.A. Copeland, Mechanistic considerations in high-throughput screening, Anal. Biochem. 320 (2003) 1-12. (Pubitemid 36937062)
36. M.W. Martin, J. Newcomb, J.J. Nunes, D.C. McGowan, D.M. Armistead, C. Boucher, J.L. Buchanan, W. Buckner, L. Chai, D. Elbaum, L.F. Epstein, T. Faust, S. Flynn, P. Gallant, A. Gore, Y. Gu, F. Hsieh, X. Huang, J.H. Lee, D. Metz, S. Middleton, D. Mohn, K. Morgenstern, M.J. Morrison, P.M. Novak, A. Oliveirados-Santos, D. Powers, P. Rose, S. Schneider, S. Sell, Y. Tudor, S.M. Turci, A.A. Welcher, R.D. White, D. Zack, H. Zhao, L. Zhu, X. Zhu, C. Ghiron, P. Amouzegh, M. Ermann, J. Jenkins, D. Johnston, S. Napier, E. Power, Novel 2- aminopyrimidine carbamates as potent and orally active inhibitors of Lck: synthesis, SAR, and in vivo antiinflammatory activity, J. Med. Chem. 49 (2006) 4981-4991. (Pubitemid 44201056)
37. J. Sridhar, N. Akula, N. Pattabiraman, Selectivity and potency of cyclin-dependent kinase inhibitors, AAPS J. 8 (2006) E204-E221.
38. T. Takaki, A. Echalier, N.R. Brown, T. Hunt, J.A. Endicott, M.E. Noble, The structure of CDK4/cyclin D3 has implications for models of CDK activation, Proc. Natl. Acad. Sci. USA 106 (2009) 4171-4176.
39. P.J. Day, A. Cleasby, I.J. Tickle, M. O'Reilly, J.E. Coyle, F.P. Holding, R.L. McMenamin, J. Yon, R. Chopra, C. Lengauer, H. Jhoti, Crystal structure of human CDK4 in complex with a D-type cyclin, Proc. Natl. Acad. Sci. USA 106 (2009) 4166-4170.
40. Y.S. Cho, M. Borland, C. Brain, C.H. Chen, H. Cheng, R. Chopra, K. Chung, J. Groarke, G. He, Y. Hou, S. Kim, S. Kovats, Y. Lu, M. O'Reilly, J. Shen, T. Smith, G. Trakshel, M. Vögtle, M. Xu, M. Xu, M.J. Sung, 4-(Pyrazol-4-yl)-pyrimidines as selective inhibitors of cyclin-dependent kinase 4/6, J. Med. Chem. 53 (2010) 7938-7957.